Thought Leadership
Email Page
Axinn FDA Update: Insights on the MODERN Labeling Act
Eric D. Dunbar, Chad A. Landmon
Axinn Update
November 20, 2020
Seeking "Mens Sana in Corpore Sano" in a Pandemic
Francis H. Morrison
Voice of Experience
November 17, 2020
Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge
Drew A. Hillier, Chad A. Landmon
The Center for Biosimilars
November 11, 2020
How to Protect IP Against COVID-19 Scammers Leveraging Social Media Algorithms to Legitimize Fake Products
Joshua S. Reisberg
Thomson Reuters Westlaw
November 10, 2020
Another Way to Skin the Cat? Perspectives on Using Section 2 to Challenge the Acquisition of Nascent Competitors
James L. Moore III
The Threshold
October 26, 2020
Federal Circuit to Decide Limits on Functional Claiming of Isolated Monoclonal Antibodies
Jonathan A. Harris, Drew A. Hillier
Biosimilar Development
October 22, 2020
Antitrust Enforcers Gather at the ICN 2020 Virtual Annual Conference to Tackle Challenges Presented by Digital Markets
Susan Zhu
Competition Policy International
October 6, 2020
Managing Timing of Multi-Jurisdictional Review
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 2020
How to Get Selected and Approved as a Merger Divestiture Buyer
James A. Goldfeier, Steven C. Lavender
ABA Antitrust Counselor
September 2020
Surveying the Landscape
Christopher M. Gallo, PhD, David H. Silverstein
Intellectual Property Magazine
September 29, 2020
Axinn FDA Update: A Difficult Analysis Is Not Necessarily a Deferential Analysis
Alexander V. Alfano, Michelle E. Divelbiss, Chad A. Landmon
Axinn Update
September 21, 2020
Tuning in to Covered Business Method Review's Series Finale
Eric Krause, Pan Lee
Law360
September 15, 2020
Acquisitions of Potential Competitors: The U.S. Approach and Calls for Reform
James L. Moore III, Koren W. Wong-Ervin
August 19, 2020
Liability for Japanese Companies Under U.S. Securities Laws: The Risks in Unsponsored ADRs
Donald W. Hawthorne
Axinn Updates
August 2020
Making It Rain: Rachel Adcox
Rachel J. Adcox, Jetta C. Sandin
ABA Law Practice Today
August 14, 2020
FDA Extends Enforcement Discretion Period for Regenerative Medicine Products, but This Isn't a Green Light for Bad Actors
Michelle E. Divelbiss, Chad A. Landmon
Cell & Gene
August 6, 2020
FDA Informal Guidance Process
Alexander V. Alfano, Michelle E. Divelbiss, Chad A. Landmon
Lexis Practice Advisor
July 30, 2020
Second Circuit: Southern District of New York
Lisl J. Dunlop, Jetta C. Sandin
GCR Insight: US Courts Annual Review
July 24, 2020
Axinn Patent Attorneys Discuss Insulins Under the BPCIA vs Hatch-Waxman
Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
July 21, 2020
Highlights From OECD Roundtable on Conglomerate Mergers
David R. Pearl
Law360
July 13, 2020
Inclusion Matters, Now More Than Ever: Practical Suggestions for Making a Difference
Jason Murata
AIPLA Innovate Magazine
July 10, 2020
Five Core IP Legal Principles in Life Sciences
Jonathan A. Harris, Nisan C. Zaghi
Life Sciences Intellectual Property Review
July 9, 2020
Axinn IP Update: District Court Retains Subject Matter Jurisdiction But Grants Dismissal After Paragraph III Conversion
Ricardo Camposanto, Chad A. Landmon, Ted Mathias
Axinn Update
July 8, 2020
Break Up Denny’s
John D. Harkrider
Competition Policy International
July 8, 2020
Assessing the New DOJ, FTC Vertical Merger Guidelines
John D. Harkrider, Koren W. Wong-Ervin
Law360
July 6, 2020
IPR: The End of the Road for Fifth Amendment Challenges?
Aziz Burgy
World IP Review
July 6, 2020
Old Drug, New Tricks? How the BPCIA Could Increase Generic Competition for Insulins
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online / Biosimilar Development
June 23, 2020
Highlights From OECD Roundtable on Data Rights in Antitrust
Pauline (Shi) Tang
Law360
June 17, 2020
Practical Advice for Japanese Businesses When Coronavirus Prevents Performance of Contracts Governed by U.S. Law
Donald W. Hawthorne
Axinn Updates
June 2020
Highlights From OECD Roundtable on Killer Acquisitions
Angelina Whitfield***
Law360
June 16, 2020
GCR Interview: Nascent Acquisitions
Koren W. Wong-Ervin
Global Competition Review
June 12, 2020
Open Source Patent Licenses: Pitfalls and Opportunity
Drew A. Hillier, Chad A. Landmon
Bloomberg Law
June 5, 2020
Do You Have to Put Up With That? Legal Protections in the Context of Antitrust Law Investigations in the U.S. and E.U.
Nicholas E.O. Gaglio, Lindsey Strang, Susan Zhu
Compliance Berater
May 28, 2020
A Lawyer's Guide to Client Service Continuity Planning
Craig M. Reiser, Thomas G. Rohback, Eva Yung
Law360
May 22, 2020
AmEx: Beyond Transaction Platforms and Section 1
Koren W. Wong-Ervin
Competition Policy International
May 14, 2020
6 Lessons on Jury Advocacy in the Wake of a Crisis
Francis H. Morrison, John M. Tanski
Law360
May 11, 2020
ABA SciTech Brief Short Video on COVID-19: FDA Emergency Use Authorizations
Chad A. Landmon
American Bar Association
May 8, 2020
Axinn Patent Attorneys Talk ACA Pushback and the BPCIA
Ted Mathias, Stacie L. Ropka, PhD
The Center for Biosimilars
May 4, 2020
Challenging Consummated Mergers Under Section 2
Koren W. Wong-Ervin
Competition Policy International
May 3, 2020
Attorney-Client Privilege in the United States: Recent Trends in its Application to Japanese Patent Professionals
Jason Murata, John M. Tanski
AIPPI Journal
April 2020
A Close Look at European Union's AI Regulation Proposal
Thomas K. Hedemann, Matthew S. Murphy, Brooke J. Oppenheimer
Law360
April 22, 2020
Insulin Under the BPCIA: Opportunities and Obstacles
Ted Mathias, Stacie L. Ropka, PhD
Biosimilar Development
April 22, 2020
FDA’s Emergency Use Authorizations: Aggressive Action Taken to Combat COVID-19
Drew A. Hillier, Chad A. Landmon
Contract Pharma
April 20, 2020
How to Combat IP-Facilitated Digital Fraud During Pandemic
Joshua S. Reisberg, Angelina Whitfield***
Law360
April 20, 2020
Assessing Monopoly Power or Dominance in Platform Markets
Koren W. Wong-Ervin
American Bar Association
April 15, 2020
The Risks of Radicalism: Exacerbating Harms from Type I Errors
James L. Moore III, Koren W. Wong-Ervin
Competition Policy International
April 9, 2020
Virus Heightens Importance of Drug Shortage Reports to FDA
Chad A. Landmon, Nisan C. Zaghi
Law360
April 2, 2020
FDA Emergency Use Authorizations
Drew A. Hillier, Chad A. Landmon
Lexis Practice Advisor Journal
April 1, 2020
Axinn IP Update: Prosecution Counsel Beware: Statutory Bars and Inequitable Conduct
Eric D. Dunbar, Jonathan A. Harris
Axinn Update
March 19, 2020
The 2019 Axinn Survey of U.S. Litigation Involving Japanese Companies
Rachel J. Adcox, Donald W. Hawthorne, Jason Murata, John M. Tanski
March 2020
Balancing Settlements, Motions After Fed. Circ. Serta IP Ruling
Alexander V. Alfano, Stacie L. Ropka, PhD
Law360
March 16, 2020
Antitrust Issues in Health Care Transactions
Adam Cella
American Health Lawyers Association
March 2020
Navigating Uncertainty in Digital Health Patent Eligibility
Ross E. Blau, Joshua S. Reisberg
Law360
March 2, 2020
Axinn IP Update: Six Patents Directed to Humanized Monoclonal Antibodies Fall at PTAB
Ross E. Blau, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
February 27, 2020
What ACA's Uncertain Future Means for Biologics Patents
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
Law360
February 27, 2020
Chevron’s Hard-Hitting Footnote Nine Revived by Kisor v. Wilkie and Recent Decisions on Deference
Alexander V. Alfano, Michelle E. Divelbiss, Chad A. Landmon
FDLI
February 21, 2020
Axinn IP Update: Settlement Practice in Light of Pending Motions
Alexander V. Alfano, Stacie L. Ropka, PhD
Axinn Update
February 20, 2020
A Deep Dive Into the Antitrust Claims Against Facebook
Daniel S. Bitton, Angelina Whitfield***
The Daily Journal
February 14, 2020
Fed. Circ. May Limit USPTO’s Standing to Intervene
Michelle E. Divelbiss
Law360
February 12, 2020
Quest Integrity v. Cokebusters Puts Cloud-Based Medical Diagnostic Patents at Risk of On-Sale Bar
David K. Ludwig, Matthew S. Murphy
Medical Device and Diagnostic Industry
February 7, 2020
FDA Administrative Decision Challenges
Alexander V. Alfano, Chad A. Landmon
Lexis Practice Advisor
January 30, 2020
Pharmaceutical Experience Matters in Defending Pharmaceutical Securities Cases
Matthew J. Becker, Donald W. Hawthorne, Chad A. Landmon
Axinn Update
January 2020
Axinn IP Update: SCOTUS Passes on Refining Subject Matter Eligibility Doctrine
Thomas K. Hedemann, Gabriella M. McIntyre
Axinn Update
January 13, 2020
Method of Treatment Eligibility
Aziz Burgy, Christopher M. Gallo, PhD, Gabriella M. McIntyre
Intellectual Property Magazine
January 9, 2020
Axinn IP Update: No “Single-Entity” Requirement for Section 271(g) Liability
Ricardo Camposanto, Thomas K. Hedemann, David K. Ludwig
Axinn Update
December 30, 2019
Axinn IP Update: Federal Circuit Addresses BPCIA Safe Harbor, Damages
Ted Mathias, Matthew S. Murphy, Nisan C. Zaghi
Axinn Update
December 19, 2019
Open the Floodgates: The Potential Impact on Litigation Against FDA if the Supreme Court Reverses or Curtails Chevron Deference
Alexander V. Alfano, Michelle E. Divelbiss, Chad A. Landmon
FDLI
December 18, 2019
Who’s Who Legal – Thought Leaders Competition
Daniel S. Bitton, Lisl J. Dunlop, John D. Harkrider
Who’s Who Legal
December 2019
3 Strategies to Manage Case Scope in ANDA Patent Litigation
Aziz Burgy, Eric D. Dunbar, Christopher M. Gallo, PhD, Brett Garrison
Law360
December 10, 2019
Little Impact Post-Arthrex for Biologic Patents at the PTAB
Drew A. Hillier, Gabriella M. McIntyre, Stacie L. Ropka, PhD
The Center for Biosimilars
December 3, 2019
U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?
Chad A. Landmon
IPWatchdog
November 25, 2019
Fed Circ. Ruling May Affect Eligibility of Life Sciences Patents
David K. Ludwig, Ted Mathias
Law360
November 21, 2019
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Leslie C. Overton
GCR Insight: E-Commerce Competition Enforcement Guide
November 20, 2019
Can the FDA Salvage Interchangeable Follow-On Biologics?
Michelle E. Divelbiss, Ted Mathias, Stacie L. Ropka, PhD
BioProcess Online / Biosimilar Development
November 19, 2019
Axinn IP Update: Section 287(c) Immunity Has Its Limits
Ross E. Blau, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
November 18, 2019
Curing the Drug Label as Prior Art Malady at the PTAB
Aziz Burgy, Christopher M. Gallo, PhD
IPWatchdog
November 13, 2019
New Calif. Pay-For-Delay Law May Hurt Those It Aims to Help
Chantelle D. Ankerman, Chad A. Landmon
Law360
November 5, 2019
Protecting Intellectual Property in the Era of Intelligent Machines
Thomas K. Hedemann, Matthew S. Murphy
Connecticut Bar Association
Fall 2019
Let Me Ride: No Short-Cuts in the Antitrust Analysis of Ride Hailing
Daniel S. Bitton, David R. Pearl, Patrick Shaw
CLA: Competition, Fall 2019, Vol 29, No. 2
Fall 2019
Axinn IP Update: No Collateral Estoppel after PTAB Ruling on IPR
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
October 9, 2019
Failure to Launch: The Patent Thicket Delay of US Biosimilars
Chantelle D. Ankerman, Ted Mathias, Stacie L. Ropka, PhD
Law360
October 9, 2019
Axinn IP Update: PTAB Abused its Discretion in Denying Patentee Leave to Correct Chain of Priority
Alexander V. Alfano, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
October 4, 2019
Managing Timing of Multi-Jurisdictional Review
John D. Harkrider, Michael J. O'Mara
GCR Insight: Merger Remedies Guide
October 1, 2019
Fed. Circ. Muddies Waters on Method-Of-Treatment Patents
Thomas K. Hedemann, David K. Ludwig
Law360
September 4, 2019
Fixing the Follow-On Insulin Regulatory Approval "Dead Zone"
Christopher M. Gallo, PhD, Chad A. Landmon
BioSimilar Development
September 4, 2019
Axinn IP Update: Federal Circuit Says Method of Treatment Claims Are Not Per Se Eligible Under Section 101
Ross E. Blau, Ted Mathias
Axinn Update
August 29, 2019
Can We Have Mergers Without Tears? Understanding the Basics of Merger Review
Michael L. Keeley
Our Curious Amalgam
August 26, 2019
Recent FDA Court Decision Shows Potential Impact of SCOTUS Deference Decision
Alexander V. Alfano, Chad A. Landmon
Bloomberg Law and Bloomberg Big Law Business
August 20, 2019
Axinn Insights on U.S. Litigation for Japanese Companies: The Duty to Preserve Documents and Implement Litigation Holds in U.S. Civil Litigation
Rachel J. Adcox, Donald W. Hawthorne, Jason Murata, John M. Tanski
August 19, 2019
How 2 Recent Court Cases Could Impact Follow-On Biologics Strategy
Drew A. Hillier, Stacie L. Ropka, PhD
Biosimilar Development
July 23, 2019
What High Court's Kisor Ruling Means for FDA Decisions
Alexander V. Alfano, Chad A. Landmon
Law360
July 16, 2019
UnitedHealth-DaVita and Trends in Vertical Merger Enforcement
Adam Cella, Jeny M. Maier
AHLA PG Briefing
July 11, 2019
FDA's Aggressive Enforcement Against Stem Cell Companies Starting to Ripen
Chad A. Landmon
Bloomberg BNA Insights
June 27, 2019
How I Made Partner: Jeny Maier
Jeny M. Maier
Law.com
June 19, 2019
Judge Moves Aetna/CVS Deal Into Unchartered Tunney Act Waters
Lisl J. Dunlop, Jeny M. Maier
Bloomberg Law
June 4, 2019
Biologic Labels and Induced Patent Infringement: A Perspective on Evolving U.S. Law
Drew A. Hillier, Stacie L. Ropka, PhD
BioProcess International
May 17, 2019
Information Exchange Counseling in the Digital Age
Kail J. Jethmalani
The Antitrust Counselor
May 15, 2019
Axinn IP Update: FDA Issues Final Guidance on Interchangeability of Biologics
Christopher M. Gallo, PhD, Stacie L. Ropka, PhD
Axinn Update
May 14, 2019
Who’s Who Legal – Thought Leaders Competition and Thought Leaders Global Elite
John D. Harkrider
Who’s Who Legal
May 9, 2019
Navigating Vertical Mergers in Healthcare Through a Shifting Enforcement Landscape
Lisl J. Dunlop, Cristina M. Fernandez
Competition Policy International
May 7, 2019
Antitrust Updates from Latin and South America
Kail J. Jethmalani
ABA Section of Antitrust Law
April 26, 2019
The Capitol Forum Thought Leaders Series
Lisl J. Dunlop, Jeny M. Maier
April 25, 2019
Competition in Display Ad Technology: A Retrospective Look at Google/Doubleclick and Google/Admob
Daniel S. Bitton, Stacie Soohyun Cho, David R. Pearl
Competition Policy International
April 17, 2019
2018 Year-End Roundup of Federal Circuit Obviousness Decisions in Biopharma
Jonathan A. Harris, Drew A. Hillier, Nisan C. Zaghi
Westlaw Journal Pharmaceutical
April 9, 2019
Justices May Be Ready to Narrowly Overturn 'Auer'
Chad A. Landmon
Law360
March 28, 2019
FDA Doubles Down in Its Updated Biologics Naming Guidance
Chad A. Landmon
The Center for Biosimilars
March 19, 2019
Axinn IP Update: Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals, Inc.
Thomas K. Hedemann, Stacie L. Ropka, PhD
Axinn Update
March 18, 2019
Axinn IP Update: U.S. Supreme Court Holds That Copyright Office Must Grant Copyright Registration Before Infringement Suit Can Be Filed
Rebecca L. Clegg, Delphine Knight Brown, Joshua S. Reisberg
Axinn Update
March 5, 2019
Status Quo Maintained: FDA Reverses Course on Generic Product Labeling
Eric D. Dunbar, Chad A. Landmon
FDLI Update
March 1, 2019
Method-of-Treatment Patent Eligibility: Step 1 and Done?
Thomas K. Hedemann, David K. Ludwig
Law360
February 5, 2019
A Hard Choice for Abbreviated Biologics License Applicants
Drew A. Hillier, Ted Mathias, Stacie L. Ropka, PhD
Law360
February 4, 2019
Axinn IP Update: Federal Circuit Affirms No Public Use Via Implied Confidentiality
Alexander V. Alfano, Ryan A. Cook, Ted Mathias, Stacie L. Ropka, PhD
Axinn Update
January 30, 2019
Stem Cell Companies Beware: FDA May Come Knocking
Chad A. Landmon
Bloomberg BNA Insights
January 28, 2019
Axinn IP Update: U.S. Supreme Court Ruling Leaves On-Sale Bar Unchanged
Alexander V. Alfano, Chad A. Landmon, Stacie L. Ropka, PhD
Axinn Update
January 23, 2019
United States – E-Commerce and Big Data: Merger Control
Daniel S. Bitton, Brandon Boxbaum
GCR Insight: E-Commerce Competition Enforcement Guide
January 10, 2019
Bringing Light to the DOJ’s Cartel Fine Methodology with the Auto Parts Plea Agreements
Daniel K. Oakes
The Antitrust Bulletin
December 1, 2018
Patent Dance Developments: A Tale of 2 Antibodies
Ted Mathias, Stacie L. Ropka, PhD, Nisan C. Zaghi
Law360
October 26, 2018
Axinn FDA Update: SUPPORT for Patients and Communities Act
Chad A. Landmon
Axinn Update
October 9, 2018
Sports and Labor Monopsonies: Learning from the Pros
Chris Brassfield**, Nicholas E.O. Gaglio
ABA Antitrust Law Monopoly Matters (Vol. 16, No. 2)
Fall 2018
Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio, Second Edition
Chad A. Landmon
ABA: Section of Intellectual Property Law
October 2, 2018
United States: Mergers
Mark D. Alexander
The Antitrust Review of the Americas 2019
September 24, 2018
FDA Focus: What Axinn's Practice Chair Is Watching
Chad A. Landmon
Law360
September 14, 2018
The CRISPR Tug of War
Rebecca L. Clegg, Ted Mathias, Stacie L. Ropka, PhD
IPWatchdog
August 17, 2018
Vertical Healthcare Merger Review After United States v. AT&T, Inc.
Arielle Koppell, Jeny M. Maier
AHLA Weekly
July 27, 2018
Antitrust in the Trump Administration: A Tough Enforcer That Believes in Limited Government
John D. Harkrider
ABA Antitrust Magazine
July 20, 2018
Connecting the Dots: Tracing the DOJ’s Inclusion of Indirect Commerce in Auto Parts Criminal Penalties
Daniel K. Oakes
ABA Antitrust Magazine
July 20, 2018
Beyond the Merits: Generic Company Defense Strategies
Joshua S. Reisberg
Pharmaceutical Executive
June 29, 2018
Integrating Trade Secrets into a Comprehensive IP Strategy
Jason Murata, John M. Tanski
Today's General Counsel
June 19, 2018
Criminal Antitrust Enforcement Has A New Leader
John W. O'Toole, Tiffany Rider
Law360
May 21, 2018
2017 Federal Circuit Obviousness Decisions in Biopharma: 5 Takeaways
Ross E. Blau, Jonathan A. Harris, Drew A. Hillier
Westlaw Journal
April 17, 2018
AHLA Antitrust Practice Group Alert
Adam Cella, Jeny M. Maier
American Health Lawyers Association
March 27, 2018
Chapter on Non-Prosecutorial Activities
Rachel J. Adcox, James A. Goldfeier, Kail J. Jethmalani, Kenina J. Lee
DOJ Civil Antitrust Practice and Procedure Manual
2018

View Archived Thought Leadership ›